AHCO — AdaptHealth Corp.

AdaptHealth Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Q1 2026 revenue reached $819.8 million, a 5.4% increase year-over-year, exceeding guidance by approximately $22 million.
• Organic Growth: Adjusted for acquisitions and dispositions, organic growth was 9.1%, with 4% from the core business and 5.1% from the new capitated contract.
• Adjusted EBITDA: Reported at $121.2 million, representing a margin of 14.8%, which was about $7 million below guidance due to elevated labor costs.
• Capitated Revenue: Contributed $74.9 million, with a membership count increasing 7x year-over-year to 15 million.
• Cash Flow: Cash flow from operations was $93.7 million, while free cash flow was negative $27.5 million, driven by capital expenditures of $121.2 million.

2. Strategic Updates and Business Highlights

• Capitated Agreement Transition: Successfully transitioned hundreds of thousands of patients under a new capitated agreement, establishing 35 new locations and becoming the exclusive provider for over 10 million members.
• Infrastructure Investments: Progress on AI-enabled initiatives and a patient-facing digital platform, with 25% of scheduling now touchless.
• Portfolio Optimization: Continued focus on core segments, with a strategic exit from non-core assets leading to a decline in Wellness at Home revenue, but an 11% organic growth when adjusted for disposals.

3. Forward Guidance and Outlook

• Revenue Projections: Full-year net revenue guidance raised by $10 million to a range of $3.45 billion to $3.52 billion.
• Adjusted EBITDA Guidance: Maintained at $680 million to $730 million for the year.
• Q2 Expectations: Projected revenue of $840 million to $860 million with an adjusted EBITDA margin of approximately 19%.

4. Bad News, Challenges, or Points of Concern

• Elevated Labor Costs: Q1 saw $12 million in higher-than-expected labor costs, which are expected to normalize by Q2 but impacted EBITDA.
• Free Cash Flow: Negative free cash flow in Q1 due to high capital expenditures, although expected to improve in the latter half of the year.
• Market Dynamics: While the company is optimistic about growth, there are ongoing challenges in managing costs associated with the rapid transition to capitated contracts.

5. Notable Q&A Insights

• Organic Growth Breakdown: Clarified that 4% of organic growth came from the core business excluding capitated arrangements, with expectations for acceleration in Q2.
• Future EBITDA Trends: Projected a ramp-up in EBITDA margins as labor costs stabilize and the full impact of capitated revenue is realized.
• Capitated Contracts Pipeline: Positive outlook on new capitated arrangements, with expectations for announcements soon, indicating active discussions and interest.
• Diabetes Segment: Noted improvements in execution within the diabetes business, with no significant changes in the marketplace affecting growth.

In summary, AdaptHealth's Q1 2026 results reflect strong revenue growth and strategic advancements, particularly in capitated agreements, despite challenges with elevated labor costs and negative free cash flow. The company remains optimistic about future growth and operational improvements.